Literature DB >> 21036380

Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Jennifer L Kirchherr1, Jennifer Hamilton, Xiaozhi Lu, S Gnanakaran, Mark Muldoon, Marcus Daniels, Webster Kasongo, Victor Chalwe, Chanda Mulenga, Lawrence Mwananyanda, Rosemary M Musonda, Xing Yuan, David C Montefiori, Bette T Korber, Barton F Haynes, Feng Gao.   

Abstract

Neutralizing antibodies (Nabs) are thought to play an important role in prevention and control of HIV-1 infection and should be targeted by an AIDS vaccine. It is critical to understand how HIV-1 induces Nabs by analyzing viral sequences in both tested viruses and sera. Neutralization susceptibility to antibodies in autologous and heterologous plasma was determined for multiple Envs (3-6) from each of 15 subtype-C-infected individuals. Heterologous neutralization was divided into two distinct groups: plasma with strong, cross-reactive neutralization (n=9) and plasma with weak neutralization (n=6). Plasma with cross-reactive heterologous Nabs also more potently neutralized contemporaneous autologous viruses. Analysis of Env sequences in plasma from both groups revealed a three-amino-acid substitution pattern in the V4 region that was associated with greater neutralization potency and breadth. Identification of such potential neutralization signatures may have important implications for the development of HIV-1 vaccines capable of inducing Nabs to subtype C HIV-1.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036380      PMCID: PMC3007099          DOI: 10.1016/j.virol.2010.09.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  61 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

2.  Founder effects in the assessment of HIV polymorphisms and HLA allele associations.

Authors:  Tanmoy Bhattacharya; Marcus Daniels; David Heckerman; Brian Foley; Nicole Frahm; Carl Kadie; Jonathan Carlson; Karina Yusim; Ben McMahon; Brian Gaschen; Simon Mallal; James I Mullins; David C Nickle; Joshua Herbeck; Christine Rousseau; Gerald H Learn; Toshiyuki Miura; Christian Brander; Bruce Walker; Bette Korber
Journal:  Science       Date:  2007-03-16       Impact factor: 47.728

3.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

Authors:  Joris Hemelaar; Eleanor Gouws; Peter D Ghys; Saladin Osmanov
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Authors:  Tongqing Zhou; Ivelin Georgiev; Xueling Wu; Zhi-Yong Yang; Kaifan Dai; Andrés Finzi; Young Do Kwon; Johannes F Scheid; Wei Shi; Ling Xu; Yongping Yang; Jiang Zhu; Michel C Nussenzweig; Joseph Sodroski; Lawrence Shapiro; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 8.  The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

Authors:  Bette Korber; S Gnanakaran
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

9.  Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.

Authors:  Feng Gao; Richard M Scearce; S Munir Alam; Bhavna Hora; Shimao Xia; Julie E Hohm; Robert J Parks; Damon F Ogburn; Georgia D Tomaras; Emily Park; Woodrow E Lomas; Vernon C Maino; Susan A Fiscus; Myron S Cohen; M Anthony Moody; Beatrice H Hahn; Bette T Korber; Hua-Xin Liao; Barton F Haynes
Journal:  Virology       Date:  2009-09-09       Impact factor: 3.616

10.  Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity.

Authors:  Ron Diskin; Paola M Marcovecchio; Pamela J Bjorkman
Journal:  Nat Struct Mol Biol       Date:  2010-03-31       Impact factor: 15.369

View more
  15 in total

1.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Authors:  Haili Tang; James E Robinson; S Gnanakaran; Ming Li; Eric S Rosenberg; Lautaro G Perez; Barton F Haynes; Hua-Xin Liao; Celia C Labranche; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine.

Authors:  Maria Blasi; J Harris Carpenter; Bala Balakumaran; Andrea Cara; Feng Gao; Mary E Klotman
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

6.  Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.

Authors:  George K Lewis; Timothy R Fouts; Sani Ibrahim; Brian M Taylor; Rachita Salkar; Yongjun Guan; Roberta Kamin-Lewis; James E Robinson; Anthony L Devico
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

7.  Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Authors:  Michael Lopker; Juliet Easlick; Sarah Sterrett; Julie M Decker; Hannah Barbian; Gerald Learn; Brandon F Keele; James E Robinson; Hui Li; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

8.  Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment.

Authors:  Zahra F Parker; Ann H Rux; Amber M Riblett; Fang-Hua Lee; Lubica Rauova; Douglas B Cines; Mortimer Poncz; Bruce S Sachais; Robert W Doms
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-15       Impact factor: 2.205

9.  A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein.

Authors:  Anurag Sethi; Jianhui Tian; Cynthia A Derdeyn; Bette Korber; S Gnanakaran
Journal:  PLoS Comput Biol       Date:  2013-05-16       Impact factor: 4.475

10.  Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.

Authors:  Antoine Chaillon; Martine Braibant; Stéphane Hué; Samia Bencharif; David Enard; Alain Moreau; Assia Samri; Henri Agut; Francis Barin
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.